OncoMatch/Clinical Trials/NCT06444815
A Study of VET3-TGI in Patients With Solid Tumors
Is NCT06444815 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including VET3-TGI and Pembrolizumab for solid tumor, adult.
Treatment: VET3-TGI · Pembrolizumab — VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with pembrolizumab in patients with solid tumors (STEALTH-001).
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Colorectal Cancer
Head and Neck Squamous Cell Carcinoma
Cervical Cancer
Renal Cell Carcinoma
Melanoma
Mesothelioma
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Kidney function
Liver function
Demonstrate adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USC/Norris Comprehensive Cancer Center · Los Angeles, California
- UC Irvine Health · Orange, California
- University of Miami · Miami, Florida
- Community Health Network · Indianapolis, Indiana
- UPMC- Hillman Cancer Center · Pittsburgh, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify